Study Shows Acriflavine May Treat Cutaneous Leishmaniasis by Reducing Inflammation Rather Than Killing Parasites
A new study in mice found that acriflavine, an antimicrobial compound, significantly reduced lesion size in cutaneous leishmaniasis without lowering parasite levels. Instead, the drug appeared to work by limiting dendritic cell activation and reducing IFN-γ-driven immune inflammation at the infection site. The findings suggest a potential host-directed therapy that targets immunopathology rather than the parasite itself, a novel approach for a disease with frequently failing treatments.
Researchers studying cutaneous leishmaniasis — a parasitic skin disease caused by Leishmania major — found that acriflavine treatment significantly reduced lesion size in infected mice, but did so through an unexpected mechanism. Rather than reducing parasite burden, acriflavine lowered the frequency of dendritic cells within lesions and decreased their expression of MHC class II molecules, which in turn correlated with fewer IFN-γ-producing CD4 T cells at the infection site. This points to the drug's ability to inhibit hypoxia-driven responses as the likely mechanism, since Leishmania-infected skin is known to be hypoxic in both mice and humans. The study challenges the assumption that effective treatment must focus on parasite clearance, highlighting instead that excessive protective immune responses can themselves drive tissue damage and worse clinical outcomes. The authors propose acriflavine as a candidate host-directed therapeutic and suggest that targeting hypoxia-associated pathways more broadly could offer a new strategy for reducing inflammatory pathology in cutaneous leishmaniasis.
What's missing
The study is conducted exclusively in a mouse model (L. major infection); it is not yet known whether these findings translate to human patients or other Leishmania species. The paper does not address optimal dosing, safety profile, or potential long-term consequences of dampening the immune response, such as increased risk of parasite dissemination or reactivation. The mechanistic link between acriflavine's HIF inhibition and the observed reduction in dendritic cell activation is correlational and not yet directly established.
What different sources said
- bioRxivCenter
Acriflavine treatment attenuates inflammatory pathology in cutaneous leishmaniasis independently of parasite control
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.